Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

November 27, 2021

Study Completion Date

November 27, 2021

Conditions

DepressionCancerPalliative Care

Interventions

DRUG

Ketamine Hydrochloride

Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT03410446 - Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care | Biotech Hunter | Biotech Hunter